Mylan N.V. Long Term Debt

The latest long-term debt for MYL is $9.1B as of September 2020. That compares with $12B in the prior-year period — down 27.0% year over year. Investors often review this figure alongside Mylan N.V.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, MYL's long-term debt moved from $12B to $9.1B — a 27.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mylan N.V.'s operating scale or balance-sheet position.

A long-term debt figure of $9.1B for MYL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MYL's long-term debt ($9.1B), review year-over-year change from $12B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Mylan N.V.'s long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.